Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

ST Germain D J Co. Inc. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

The stock's rise snapped a five-day losing streak.

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's fourth consecutive day of losses.

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...